Key Insights

Highlights

Success Rate

95% trial completion (above average)

Published Results

12 trials with published results (19%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

3.1%

2 terminated out of 64 trials

Success Rate

95.2%

+8.7% vs benchmark

Late-Stage Pipeline

19%

12 trials in Phase 3/4

Results Transparency

30%

12 of 40 completed with results

Key Signals

12 with results95% success

Data Visualizations

Phase Distribution

47Total
Not Applicable (20)
Early P 1 (1)
P 1 (5)
P 2 (9)
P 3 (10)
P 4 (2)

Trial Status

Completed40
Unknown9
Recruiting7
Withdrawn4
Active Not Recruiting2
Terminated2

Trial Success Rate

95.2%

Benchmark: 86.5%

Based on 40 completed trials

Clinical Trials (64)

Showing 20 of 20 trials
NCT01631617Phase 2Recruiting

Effects of Treatments on Atopic Dermatitis

NCT07011706Phase 2Active Not Recruiting

ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

NCT07414602Phase 1RecruitingPrimary

A Phase I Study of Single Subcutaneous Dose of SHR-1894 in Healthy Subjects

NCT07428954CompletedPrimary

Using Artificial Intelligence to Help Doctors Identify Different Skin Conditions and Improve Patient Care

NCT07054528Active Not Recruiting

Multicentre Real-life Data Collection Study With CareMin650™ in the Prevention and Treatment of Oral Mucositis and Radio- and/or Chemo-induced Dermatitis

NCT02558738Completed

Non Interventional Clinical Investigation of Ectoin Ear Spray in Skin Treatment of Outer Ear Canal Irritations

NCT01840605Phase 3CompletedPrimary

A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis

NCT06436183Phase 2Completed

A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

NCT05611346Not ApplicableRecruitingPrimary

HYPNOsis in the Management of Atopic Dermatitis in Children and Teenagers

NCT06353087Recruiting

Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)

NCT03563066Phase 2Completed

Effect of Benralizumab in Atopic Dermatitis

NCT06850389RecruitingPrimary

PMCF Investigation of Medical Device ChitoCare® Medical

NCT07056569Not ApplicableRecruiting

Post-Marketing Clinical Follow-Up Trial to Evaluate the Performance and Safety of the Medical Device 047 TD Dermatitis Cream in Adults and Children With Atopic and Contact Dermatitis Symptoms Confirmed by Clinical Parameters

NCT05001139Not ApplicableCompletedPrimary

Clinical Investigation on the Efficacy and Safety of Relizema Ecofoam

NCT06835192Not ApplicableCompletedPrimary

Impact of Combining Incontinence-associated Dermatitis Prevention and Management Course and Directive Wheel Chart

NCT04826471Not ApplicableCompletedPrimary

Clinical Investigation on the Performance and Safety of DermoRelizema Ecofoam

NCT02724449Not ApplicableCompletedPrimary

A Clinical Evaluation of 3M Cavilon Advanced Barrier Film for the Treatment of Incontinence Associated Dermatitis (IAD)

NCT03024671Not ApplicableRecruitingPrimary

Epicutaneous Testing of Cosmetics for Skin Compatibility

NCT05891743CompletedPrimary

Prevalence of Skin Sensitization and Dermatitis Among Epoxy-exposed Workers in the Wind Turbine Industry.

NCT01916980Phase 3Completed

Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Eczema/Dermatitis and Dermal Pruritus (MK-4117-202)

Scroll to load more

Research Network

Activity Timeline